The 2nd LNP Immunogenicity and Toxicity Summit is set to unite 100+ PKPD, Immunology, Safety, Toxicology experts from biopharma and academia. This is your opportunity to join...

The field of targeted covalent therapeutics is seeing a surge of activity, with both new and established companies investing heavily in the space. The inaugural Covalent Drug...

Welcome to the 8th Oncolytic Virotherapy Summit: Engineering Oncolytic Viruses Towards Revolutionary Anti-Cancer Immunotherapies Recent years have seen highly promising and...

Following proof of concept in oncology, misfolded and aggregated pathological proteins across CNS indications are the new frontier for protein degradation technologies. Heading...

With 2023 welcoming newly FDA-approved gene therapies from BioMarin, Krystal Biotech and Sarepta Therapeutics, many more treatments are hot on their heels for approval,...

Advance Scalability, Accessibility and Affordability of Autologous Cell Therapies As the cell therapy space bears witness to an increasing number of autologous therapies...

DDR inhibitor development is evolving rapidly, marked by the continuous emergence of new targets. AstraZeneca and Merck reaffirm their commitment to DDR inhibitors, yet more...

The late-stage gene therapy pipeline is rapidly evolving, with 10+ approvals across the FDA and EMA in the past year and several more BLA filings and decisions expected by the...

Driving Innovation in Discovery and Chemistry, Validating Clinical Proof-of Concept and Streamlining CMC of Conjugates with Novel Payloads and Formats Traditional ADCs have...

With the cell and gene therapy industry surging, rapid advances in mRNA-based therapies, and the advent of DNA vaccines, the demand for quality DNA as a critical starting and...

With more than 50 interactive lectures and case-based sessions, this program provides a comprehensive update of the most important changes now impacting Nephrology with...

Advance More Personalized Therapies for Rare and Common Kidney Diseases The surge of clinical breakthroughs in SGLT2s, GLP-1s and ERAs for CKD, significant advancements to...

Determining MoA and Satisfying Regulatory Requirements In the dynamic cell therapy landscape, the challenge of potency assay development looms large, as exemplified by clinical...

Not that much time has passed since our last summit. But a lot has changed. From 2023 to 2024, the industry has made unequivocal advances, from tangible progress using...

The 4ᵗʰ Wet AMD and Diabetic Eye Disease Drug Development Summit is returning to Boston this March to unite 70+ industry-based retinal vascular experts from the likes of Bayer,...

Following the increasing interest in access to investigational medicines from patients, the harmonization of guidance and research on the value of expanded access programs...

Neuroimmunology discovery has continued to expand over the past year, with emerging and continued biology and target investigation against TREM2, RIPK1, ferroptosis, NLRP3,...

This conference will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to...

The 5th Glioblastoma Drug Development Summit is the only industry led forum for large pharma, biotech, neuro-oncologists and academic KOLs to unite alongside a dedicated panel...

BOSTON SMALL BUSINESS EXPO 2024 Join us at the Boston Small Business Expo 2024, a must-attend event for entrepreneurs and small business owners! Get ready to connect, learn,...

Following the success of the 3rd Annual Psychedelic Therapeutics and Drug Development Conference in 2023, we're thrilled to be hosting the 4th Annual event on May 23-24, 2024...